Cohort analysis of safety and efficacy of vismodegib in Italian patients from the Phase II, multicenter STEVIE study

Paolo Bossi, Ketty Peris, Piergiacomo Calzavara-Pinton, Paola Queirolo, Salvatore Alfieri, Marco Palla, Maria Teresa Rossi, Francesco Spagnolo, Sara Tambone, Cinzia Astolfi, Paolo A. Ascierto

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: To assess safety and efficacy of vismodegib in the Italian cohort from the SafeTy Events in VIsmodEgib study. Materials & methods: Data from Italian patients with locally advanced basal cell carcinoma (laBCC) or metastatic BCC were analyzed. Results: Among 182 Italian patients, adverse events occurred with similar incidence to the overall population. Overall response rate was 67.1% in laBCC, 20% in metastatic BCC; complete response rate was 33.1% overall and 37.4% in laBCC. Median time to response was 2 months in complete responders versus 3.6 months overall. Quality of life improved from baseline. Conclusion: In the Italian cohort of STEVIE, vismodegib showed a safety profile consistent with the whole population; older age did not affect safety or efficacy. ClinicalTrials.gov registration: NCT0136766.

Original languageEnglish
Pages (from-to)1091-1100
Number of pages10
JournalFuture Oncology
Volume16
Issue number16
DOIs
Publication statusPublished - Jun 2020

Keywords

  • basal cell
  • carcinoma
  • Gorlin syndrome
  • HhAntag691
  • vismodegib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Cohort analysis of safety and efficacy of vismodegib in Italian patients from the Phase II, multicenter STEVIE study'. Together they form a unique fingerprint.

Cite this